Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
TVRDthis companyTvardi Therapeutics, Inc.	$1.06	-1.75×	1.52×	0×	-0.63×	179.3%	0.0%	0.0%	0.0%	-87.0%	-126.5%	-73.7%	0.01×	1.13×	0×	2.86×	0.0%	1	-13.58	3	B-
ATNMActinium Pharmaceuticals, Inc.	$1.58	-1.25×	5.42×	471.4×	0.12×	0.8%	100.0%	-40274.4%	-37652.2%	-432.6%	-81.4%	-58.2%	0.22×	1.4×	0×	6.2×	0.0%	4	-8.02	5	S-
CALCCalciMedica, Inc.	$1.49	-3.35×	-14,896.04×	0×	-3,521.14×	-100.0%	0.0%	0.0%	0.0%	445.1%	-209.1%	-0.0%	-1.46×	0.06×	-16.26×	3.58×	0.0%	3	-15.99	1	C-
ELUTElutia Inc	$0.86	0.54×	1.04×	2.33×	-0.26×	-90.4%	53.7%	-149.8%	434.2%	192.9%	-43.9%	-162.7%	0.4×	1.87×	47.58×	2.22×	0.0%	5	-6.59	3	B+
LTRNLantern Pharma Inc.	$0.57	-1.93×	5.05×	0×	-6.26×	-1222.3%	0.0%	0.0%	0.0%	-262.0%	-21.1%	-47.5%	12.02×	-4.33×	0×	2.4×	0.0%	1	-22.94	2	C+
PDSBPDS Biotechnology Corporation	$1.09	-1.04×	3.86×	0×	-0.86×	-89.5%	0.0%	0.0%	0.0%	-372.9%	-116.5%	-77.7%	1.83×	0.32×	-5.91×	2.98×	0.0%	2	-44.34	2	C
Peer median	—	-1.25×	3.86×	0×	-0.86×	-90.4%	0.0%	0.0%	0.0%	-262.0%	-81.4%	-58.2%	0.4×	0.32×	0×	2.98×	0.0%	3	-15.99	2	—